1000577-84-3 Usage
Description
2,4-Dichlorofuro[2,3-d]pyrimidine is a furopyrimidine derivative characterized by the presence of two chlorine atoms at the 2nd and 4th positions and a furan ring fused to the pyrimidine core. This chemical structure endows it with unique properties and potential applications in various fields.
Uses
Used in Pharmaceutical Industry:
2,4-Dichlorofuro[2,3-d]pyrimidine is used as a key intermediate in the synthesis of phosphoinositide 3-kinase (PI3K) inhibitors. These inhibitors are important for the development of targeted therapies against various cancers, as PI3K plays a crucial role in cell growth, survival, and metabolism. By inhibiting PI3K, these drugs can effectively suppress tumor growth and progression.
Additionally, 2,4-Dichlorofuro[2,3-d]pyrimidine may also find applications in other industries, such as agrochemicals or materials science, due to its unique chemical properties. However, the primary focus of its use is in the pharmaceutical industry for the development of cancer treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 1000577-84-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,0,5,7 and 7 respectively; the second part has 2 digits, 8 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1000577-84:
(9*1)+(8*0)+(7*0)+(6*0)+(5*5)+(4*7)+(3*7)+(2*8)+(1*4)=103
103 % 10 = 3
So 1000577-84-3 is a valid CAS Registry Number.
1000577-84-3Relevant articles and documents
Pyrimidine derivatives, preparation method therefor and application of pyrimidine derivatives
-
Paragraph 0150; 0151; 0155; 0156; 0165; 0166, (2018/03/26)
The invention belongs to the field of drug synthesis and relates to novel pyrimidine derivatives, pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof, preparation methods of thenovel pyrimidine derivatives and the pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof and use of the novel pyrimidine derivatives and the pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof in preparation of therapeutic agents, particularly PAK inhibitors. The derivatives disclosed by the invention are represented by a general formula (I) or (II), wherein each substituent is as defined in claims.
